ProKidney (PROK)

• Market cap: $364M
• 1 day: -4.29%
• 5 days: -1.83%
• 1 month: -10.37%
• 3 months: 19.64%
• 6 months: 257.33%
• Year to date: 54.91%
• 1 year: 30.73%
• 5 years: -73.49%
• 10 years: -73.49%
• Sector: Healthcare
• Industry: Biotechnology

About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Employees: 204